AI pharmaceuticals are maturing, and data sharing needs to be broken

He admitted that AI drug design is not omnipotent, and it is still impossible to get rid of human participation, "Sometimes the molecules designed by computers are difficult to synthesize, even insurmountable obstacles, such as some covalent bonds that cannot be synthesized." Although the probability of this happening is relatively small, it also shows that drug development can not be completely left to AI."

"Drug development is a process of trial and error, whether it is based on AI platform or traditional experimental drug development, it needs to be analyzed and iterated on the basis of multiple tests in order to screen out the optimal compound." Therefore, AI technology and traditional CRO can be said to jointly catalyze drug research and development in the speed, difficulty and breadth of mutualism and fusion promotion."

Chen Chunlin said with a smile that he originally wanted to promote Zhangjiang AI Pharmaceutical Alliance, precisely because CRO companies also have an important place in the AI pharmaceutical ecosystem: many AI technology companies do not have wet laboratories, and will choose to carry out experimental cooperation with CRO companies to verify algorithms.